Issue link: http://clhia.uberflip.com/i/406567
C. IMPROVING REIMBURSEMENT MODELS .................................................................................... 26 c.1 Standardized Coordination Processes ................................................................................ 26 c.2 Development of Common National Minimum Formulary .................................................. 27 c.3 Development of High Cost Drug Strategy ........................................................................... 28 D. IMPROVING COLLABORATION WITH KEY STAKEHOLDERS ......................................................... 29 d.1 Introduction of Prescribing Committees ........................................................................... 29 d.2 Encouraging Active Consumerism ..................................................................................... 30 d.3 Expanding Pharmacists' Scope of Practice ........................................................................ 31 E. ENSURING ACCESS TO ORPHAN DRUGS ..................................................................................... 32 e.1 Collaborative End-to-End Approach to Approval and Funding of Orphan Drugs .............. 32 4. CONCLUSION & PRIORITIES FOR REFORM .................................................................................. 33 APPENDIX (LIST OF RECOMMENDATIONS) ................................................................................. 35